Organization
Sinovac Life Sciences
11 clinical trials
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of Novel Coronavirus Broad-spectrum Neutralizing Antibody SA55 Injection in the Treatment of Mild/Moderate COVID-19 PatientsStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Randomized, Double-blind, Controlled Phase Ⅰ and Phase Ⅲ Clinical Trial to Evaluate the Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old PopulationStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱb Clinical Trial, to Evaluate the Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 3 to 17 Years.Status: Completed, Estimated PCD: 2021-08-01
Clinical trial
An Open-label Combined Randomized Double-blind, Positive Control Clinical Trial in Subjects Aged 2 Months (Minimum 6 Weeks) and Above to Preliminary Evaluate the Safety and Immunogenicity of a 13-valent Pneumococcal Polysaccharide Conjugate VaccineStatus: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
A Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray, Among Close Contact With COVID-19 PeopleStatus: Active (not recruiting), Estimated PCD: 2022-12-30
Clinical trial
Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel：An Open-label, Blank-controlled StudyStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety, Tolerance and Pharmacokinetics of A Broad-Spectrum Neutralizing Antibodies SA55 Injection of COVID-19 in Healthy AdultsStatus: Recruiting, Estimated PCD: 2023-10-30
Clinical trial
Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 3~17 Years : A Multicenter,Open-label StudyStatus: Completed, Estimated PCD: 2023-03-24
Clinical trial
Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of the Third Dose Using Inactivated COVID-19 Vaccine in Population Aged 18 Years and AboveStatus: Active (not recruiting), Estimated PCD: 2022-06-19
Clinical trial
A Phase I Clinical Study of Novel Coronavirus Broad-spectrum Neutralizing Antibody SA55 Nasal Spray in Healthy PeopleStatus: Recruiting, Estimated PCD: 2023-09-30
Clinical trial
A Randomized, Double-blind, Controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 24-valent Pneumococcal Conjugate Vaccine in Adults 18 Years of Age and OlderStatus: Not yet recruiting, Estimated PCD: 2024-12-20